AZD 9150

Drug Profile

AZD 9150

Alternative Names: AZD9150; IONIS-STAT3-2.5Rx; IONIS-STAT3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3-2.5Rx; ISIS-STAT3Rx; STAT3Rx

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Eli Lilly; Isis Pharmaceuticals
  • Developer AstraZeneca; Ionis Pharmaceuticals; MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer; Malignant ascites; Solid tumours
  • Phase I/II Hepatocellular carcinoma; Non-Hodgkin's lymphoma
  • Phase I Diffuse large B cell lymphoma; Haematological malignancies

Most Recent Events

  • 16 Dec 2016 Phase-II clinical trials in Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in Belgium, Germany, Italy, Spain, United Kingdom, USA
  • 16 Dec 2016 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, Germany, Italy, Spain, United Kingdom, USA (IV)
  • 15 Dec 2016 M.D. Anderson Cancer Center and AstraZeneca plans a phase -II trial for Pancreatic, Non-small cell lung cancer and Colorectal cancer in USA (NCT02983578)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top